Century Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Century Therapeutics (via subsidiary Clade) signed exclusive license from Memorial Sloan-Kettering for iPSC technology effective August 24, 2023. Counterparty: MSK. Key terms: upfront fee [redacted], running royalties [redacted]% of Net Sales, milestone payments up to [redacted] per product, sublicense income share [redacted]–[redacted]%, patent expense reimbursement. Separately, CEO Chad Cowan transitioned from full-time to part-time Chief Scientific Officer at $296,150 annualized salary (45% bonus target) effective June 15, 2026. Also, Century surrendered 11th floor office space (31,734 sq ft) in Philadelphia for $450,922.19 termination fee, reducing lease to 12th–13th floors only.
Why this rating
MSK license is core R&D asset but heavily redacted financials prevent impact assessment. CEO downgrade and office reduction suggest financial stress; immaterial relative to $212.5M cap.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.